FDA’s Califf Clarifies Real-World Data Use

Sept. 9, 2016, 9:51 PM

It is a “total misfire” to pit randomized controlled trials against the use of real-world evidence as methods for evaluating new medical products for patients, FDA Commissioner Robert M. Califf said Sept. 8.

The commissioner of the Food and Drug Administration was addressing a move to incorporate real-world evidence, or data captured in routine medical care or from the patient directly, into the agency’s regulatory decision-making process. Real-world evidence language appears in both the House-passed 21st Century Cures bill (H.R. 6) and the Senate’s companion medical innovation effort to accelerate the development of new drugs and devices. The final agreement ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.